Dovato, a combination HIV medication, is priced at approximately $3,500 to $4,000 per month in the United States, though actual out-of-pocket costs for patients can vary significantly due to insurance, copay programs, and other factors [1][2].
What influences Dovato's price?
The price of Dovato is influenced by several factors common to branded pharmaceuticals, including research and development costs, manufacturing expenses, and marketing. The drug's single-tablet regimen, combining dolutegravir and lamivudine, also contributes to its value proposition for patients and healthcare providers [3].
How does Dovato's price compare to other HIV treatments?
Dovato's pricing falls within the range of many other branded single-tablet HIV regimens. For instance, Biktarvy, another integrase inhibitor-based single-tablet regimen, has a similar monthly price point [4]. The cost-effectiveness of any HIV treatment is often evaluated against its clinical efficacy, tolerability, and potential for long-term adherence [3].
What financial assistance is available for Dovato?
ViiV Healthcare, the manufacturer of Dovato, offers several patient assistance programs to help reduce out-of-pocket costs. These may include copay cards for commercially insured patients and patient assistance programs for uninsured or underinsured individuals, potentially lowering monthly costs significantly [1][2][5].
When does Dovato's patent expire?
Information on the specific patent expiry dates for Dovato can be found through resources like DrugPatentWatch.com. Patents for combination drugs like Dovato can be complex, potentially involving patents for the individual components and the fixed-dose combination itself. Generally, branded drugs have a period of market exclusivity before generic versions can enter the market, typically after patent expiry [6].
Can generic versions of Dovato become available?
The availability of generic versions of Dovato is contingent on patent expiry and regulatory approval. Once patents expire and any relevant exclusivity periods end, generic manufacturers can seek approval from regulatory agencies to market bioequivalent versions of the drug. This process typically leads to lower prices for HIV medications [6].
What are the clinical benefits of Dovato?
Dovato is indicated for the treatment of HIV-1 infection in adults and adolescents without a known or prior history of resistance to either component of the drug (dolutegravir or lamivudine). Clinical trials have demonstrated its efficacy in achieving and maintaining viral suppression, as well as its favorable tolerability profile [3][7].
Sources:
[1] https://www.goodrx.com/dovato
[2] https://www.pparx.org/prescription-assistance-programs/dovato/
[3] https://www.dovato.com/
[4] https://www.goodrx.com/biktarvy
[5] https://www.viivhealthcare.com/patients/patient-support/
[6] https://drugpatentwatch.com/
[7] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212554s000lbl.pdf